Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis

NCT07846683 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07846683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07846683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
December 31, 2030
Enrollment
350 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

moderately to severely active ulcerative colitis